14 October 2022>: Clinical Research
Correlation Between Trough Level of Abiraterone and Prostate-Specific Antigen (PSA) Response in Metastatic Hormone-Sensitive Prostate Cancer
Zin W. Myint 12ABCDEFG* , Jill M. Kolesar 23CDE , Joseph Robert McCorkle 2CDE , Jianrong Wu 4C , Carleton S. Ellis 23CDE , Danielle E. Otto 23CDE , Peng Wang 12ACDEDOI: 10.12659/MSM.938091
Med Sci Monit 2022; 28:e938091
Table 7 Association between HSD3B1 genotype risk allele and 1-month, 3-month, and 7-month abiraterone trough levels.
HSD3B1 genotype | N | Mean (tABI)a | P value |
---|---|---|---|
1 Month | |||
0b | 4 | 7.83 | 0.398 |
1c | 6 | 11.07 | |
3 Months | |||
0b | 4 | 12.71 | 0.678 |
1c | 5 | 10.64 | |
7 Months | |||
0b | 2 | 9.13 | 0.386 |
1c | 4 | 16.12 | |
a tABI, trough abiraterone; b homozygous (A/A) genotype; c heterozygous (C/A) genotype; HSD3B1, hydroxyl-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1. |